Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-16
    E.g., 2018-10-16

Archive Search

Pages

105 results
2:00 PM, Aug 17, 2017  |  BC Innovations | Translation in Brief

Stopping the invasion

head of the institute's Division of Molecular Carcinogenesis and CSO and co-founder of diagnostics play Agendia N.V.
4:46 PM, Jul 13, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

ASCO recommends MammaPrint to inform chemo use

of the MammaPrint test to identify women who need chemotherapy and those who do not. Agendia N.V.
test for women with HER2-positive or triple-negative breast cancers (see BioCentury, Sept. 5, 2016 ). Agendia
3:36 PM, Jul 10, 2017  |  BC Extra | Company News

ASCO recommends MammaPrint to inform chemo use

of the MammaPrint test to identify women who need chemotherapy and those who do not. Agendia N.V.
12:00 AM, Sep 05, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

MammaPrint: Phase III data

Agendia N.V. , Amsterdam, the Netherlands   Product: MammaPrint   Business: Diagnostic   Molecular target: Not applicable …
recurrence, distant metastasis-free interval was 97.8% without chemotherapy. The trial, which is a collaboration between Agendia
4:45 PM, May 13, 2016  |  BC Extra | Company News

Management tracks

June 15. Kehoe was CFO at Kraft Foods Group, now The Kraft Heinz Co. (NASDAQ:KHC). Agendia N.V.
6:05 PM, Sep 29, 2015  |  BC Extra | Company News

Management tracks

Cancer diagnostics company Agendia N.V. (Amsterdam, the Netherlands) named Mark Straley CEO. Straley was president, anatomical pathology …
6:01 PM, Aug 17, 2015  |  BC Extra | Company News

Management tracks

Molecular diagnostics play Veracyte Inc. (NASDAQ:VCYT) named Neil Barth CMO. Barth was CMO at Agendia N.V. (Amsterdam …
6:32 PM, Mar 24, 2015  |  BC Extra | Politics & Policy

CMS to emphasize clinical utility of prognostic cancer tests

in patients with colorectal cancer. The committee also considered breast cancer tests including MammaPrint from Agendia N.V.
12:00 AM, Mar 09, 2015  |  BC Week In Review | Clinical News  |  Regulatory

MammaPrint FFPE regulatory update

FDA granted 510(k) clearance to Agendia’s MammaPrint FFPE test to predict the risk of breast cancer …
a 70-gene signature chip to predict recurrence regardless of patient age or HER2 receptor status. Agendia
markets MammaPrint Fresh for fresh tumor tissue. Agendia N.V. , Amsterdam, the Netherlands   Product: MammaPrint FFPE …
6:28 PM, Jan 26, 2015  |  BC Extra | Politics & Policy

CMS to discuss prognostic tests for cancer

MLH1 ) promoter methylation. The committee will discuss breast cancer tests including MammaPrint from Agendia N.V.

Pages